Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Graduate School of Peking Union Medical College, Beijing, China.
Front Public Health. 2023 May 12;11:1164536. doi: 10.3389/fpubh.2023.1164536. eCollection 2023.
Diabetic peripheral neuropathy (DPN) causes significant illness in patients and has a negative impact on the economy. The objective of this study is to evaluate the cost and quantity of anti-diabetic drugs needed by patients with or without DPN, as well as their variation trends in Beijing between 2016 and 2018.
This observational cross-sectional study used data on diabetic patients with outpatient medication records obtained from Beijing Medical Insurance from 2016 to 2018. The medications, comorbidities, diabetes-related complications, treatment strategies, and costs of drug treatment were compared between DPN patients and non-DPN patients.
Of the 28,53,036 diabetic patients included in the study, 3,75,216 (13.15%) had DPN and 1,87,710 (50.03%) of the DPN patients were women. Compared with non-DPN patients, DPN patients used more mediations (4.7 ± 2.47 vs. 3.77 ± 2.32, < 0.0001, in 2018) to treat related complications and comorbidities (2.03 ± 1.2 vs. 1.71 ± 1.05; 2.68 ± 1.93 vs. 2.06 ± 1.86, < 0.0001, respectively, in 2018). The total annual costs of drug treatment were higher in DPN patients than in non-DPN patients (¥12583.25 ± 10671.48 vs. ¥9810.91 ± 9234.14, < 0.0001, in 2018). The usage of DDP4i increased from 2.55 to 6.63% in non-DPN patients and from 4.45 to 10.09% in DPN patients from 2017 to 2018.
The number of comorbidities, diabetic complications, medications, and annual drug treatment costs were greater in DPN patients than in non-DPN patients.
糖尿病周围神经病变（DPN）会给患者带来严重的疾病负担，对经济也有负面影响。本研究旨在评估 2016 年至 2018 年期间北京地区有或无 DPN 的糖尿病患者所需的抗糖尿病药物的数量和成本，以及它们的变化趋势。
本观察性横断面研究使用了 2016 年至 2018 年期间从北京医疗保险获得的糖尿病患者门诊用药记录数据。比较了 DPN 患者和非 DPN 患者的药物、合并症、糖尿病相关并发症、治疗策略和药物治疗费用。
在纳入研究的 2853036 例糖尿病患者中，375216 例（13.15%）患有 DPN，其中 187710 例（50.03%）为女性。与非 DPN 患者相比，DPN 患者使用更多的药物（4.7±2.47 与 3.77±2.32，<0.0001，2018 年）来治疗相关并发症和合并症（2.03±1.2 与 1.71±1.05；2.68±1.93 与 2.06±1.86，<0.0001，2018 年）。DPN 患者的药物治疗总成本高于非 DPN 患者（2018 年分别为¥12583.25±10671.48 与 ¥9810.91±9234.14，<0.0001）。2017 年至 2018 年，非 DPN 患者中 DDP4i 的使用从 2.55%增加到 6.63%，DPN 患者中从 4.45%增加到 10.09%。
与非 DPN 患者相比，DPN 患者的合并症、糖尿病并发症、药物使用和年度药物治疗费用更多。
